Core Viewpoint - Compass Therapeutics, Inc. has granted stock options to two new executives as part of its 2025 Inducement Plan, which is a material inducement for their employment [1][3]. Group 1: Stock Options Granted - The company granted non-qualified stock options to purchase 1,000,000 shares of common stock each to the newly appointed Chief Commercial Officer, Arjun Prasad, and Chief Medical Officer, Cynthia Sirard [2]. - The exercise price for the stock options is set at $5.17 per share, matching the closing price of the company's common stock on January 2, 2026 [2]. - The options have a 10-year term and will vest over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting in 36 equal monthly installments, contingent on continued service [2]. Group 2: Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics for various human diseases [4]. - The company's scientific focus includes the relationship between angiogenesis, the immune system, and tumor growth, with a pipeline targeting critical biological pathways for effective anti-tumor responses [4]. - Founded in 2014 and headquartered in Boston, Massachusetts, Compass plans to advance its product candidates through clinical development and commercialization, both as standalone therapies and in combination with other proprietary antibodies [4].